CSS LLC’s Arbutus Biopharma ABUS Stock Holding History

CSS LLC’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-10,000	Closed	-$36K	–	911
2020 Q4	$36K	Buy	+10,000	New	+$35K	﹤0.01%	768

Other funds holding ABUS

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

CSS LLC's ABUS Position: Q4 2020 in Review

CSS LLC sold out of Arbutus Biopharma (ABUS) in Q4 2020, closing a stake of 26,700 shares — an estimated $93.5K sold.

CSS LLC first reported a position in ABUS in Q3 2020 and held it in 1 quarter. The position peaked at $84K in Q3 2020. 80 funds tracked by Wall St. Rank hold ABUS as of Q4 2020.

CSS LLC reported no remaining Arbutus Biopharma position as of Q4 2020 after selling out during the quarter.
CSS LLC sold 26,700 Arbutus Biopharma shares in Q4 2020, an estimated $93.5K.
CSS LLC first reported a position in Arbutus Biopharma in Q3 2020 and held it in 1 quarter.
CSS LLC's Arbutus Biopharma position peaked at $84K in Q3 2020.
80 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q4 2020.

Based on CSS LLC's 13F filing for Q4 2020, filed 16 Feb 2021.